Author: admin

  • World’s First Lightweight High Resolution High Precision CO₂ and CH₄ Point Source Detector “MUSICO” Arrives at Tiangong Space Station via Tianzhou-10

    HKUST Led Project Marks Hong Kong’s First Scientific Payload on the National Space Station

    HONG KONG SAR – Media OutReach Newswire – 13 May 2026 – The world’s first lightweight, high‑resolution, high‑precision synergistic observatory for carbon dioxide (CO₂) and methane (CH₄) emission point sources – named “MUSICO”, Multi‑Spectral Imaging Carbon Observatory, led by The Hong Kong University of Science and Technology (HKUST) – was successfully launched aboard the Tianzhou‑10 cargo spacecraft on May 11 and has arrived at China’s Tiangong Space Station. This is not only Hong Kong’s first scientific payload deployed on the national space station, but also a historic breakthrough for the city in the development of high‑end aerospace instruments. The project fully demonstrates Hong Kong’s strong capability to build national‑level cutting-edge scientific payloads, to participate in long‑term space station missions, and to play a key role in addressing global climate change while serving the nation’s strategic “carbon peak and carbon neutrality” goals.

    The project is led by an interdisciplinary research team from HKUST, comprising experts from the Department of Civil and Environmental Engineering, the Division of Emerging Interdisciplinary Areas, the Division of Environment and Sustainability, the Department of Computer Science and Engineering, and the Division of Public Policy. In late 2024, the project received formal approval from the Technology and Engineering Center for Space Utilization of the Chinese Academy of Sciences (CSU.CAS), the general research center for the Space Utilization System. It is jointly developed with the CAS Changchun Institute of Optics, Fine Mechanics and Physics, and funded by the Special Call (Aerospace Technology) of the Innovation and Technology Support Program under the Innovation and Technology Commission of the HKSAR Government.

    MUSICO is a lightweight, high‑resolution, high‑precision greenhouse gas point‑source detection payload capable of accurately measuring CO₂ and CH₄ — two major greenhouse gases — from space. Smaller than a domestic washing machine, the instrument maintains extra-high spectral resolution and one hundred‑meter spatial resolution. By analyzing intensity changes of sunlight over specific spectral bands as it passes through the atmosphere and reflects off the Earth’s surface, MUSICO identifies gas‑specific absorption features to determine gas concentrations and pinpoint individual emission sources, enabling effective monitoring of key facilities such as power plants and landfills.

    Prof. SUN Dong, Secretary for Innovation, Technology and Industry of the HKSAR Government, remarked, “This HKUST led project represents Hong Kong’s first scientific payload aboard the Tiangong Space Station, a major milestone for Hong Kong in the nation’s space missions. The national 15th Five Year Plan identifies accelerating green and low carbon transition, building a space powerhouse, and achieving carbon peak as key priorities. The successful deployment of a payload autonomously developed by a Hong Kong research team on Tiangong powerfully demonstrates that Hong Kong scientists possess top tier research and technology translation capabilities in frontier fields such as aerospace technology and green low carbon science, providing the nation with high quality, verifiable scientific data to accelerate the realization of the dual carbon goals.”

    Prof. Nancy IP, President of HKUST, said, “We are deeply honored that our HKUST research team can participate in scientific missions on the national space station, and we sincerely thank the nation and the HKSAR Government for their long‑standing trust and support. This project not only highlights HKUST’s accumulated strengths in aerospace engineering, satellite remote sensing, and environmental engineering, but also proves that Hong Kong’s research capabilities can make substantial contributions on the nation’s highest‑level aerospace platforms. As the world’s first lightweight high‑precision greenhouse gas point‑source detection payload, MUSICO will continue to operate on the national space station, providing autonomous, controllable, high‑reliability CO₂ and CH₄ emission monitoring data that directly support the nation’s dual‑carbon goals and provide scientific backing for the ‘Beautiful China’ initiative and global climate governance.”

    President Ip added, “In recent years, HKUST has been deepening its efforts in deep‑space exploration and low‑orbit satellite technology — following the successful launch of Hong Kong’s first higher‑education satellite in 2023, we are now actively participating in the nation’s Chang’e‑8 lunar exploration mission. Looking ahead, HKUST will continue to leverage its strengths in artificial intelligence, robotics, and materials science to accelerate the translation of space‑related technologies and nurture high‑end talent, contributing to the nation’s accelerated drive to build a space powerhouse and achieve green, low‑carbon, high‑quality development.”

    Prof. SU Hui, Project Lead, Chair Professor of the Department of Civil and Environmental Engineering and Global STEM Professor at HKUST, said, “The development of MUSICO involved overcoming multiple critical technical challenges — namely, how to achieve high spectral resolution, fine spatial resolution, and synergistic multi‑gas observation under strict size and weight constraints. The team conducted extensive testing and optimization in optical design, precision manufacturing, and system integration to ensure the instrument can deliver reliable, accurate greenhouse gas data over long periods under high‑speed operation and extreme space environments. Successfully integrating these key technologies into a lightweight payload represents a landmark engineering and scientific achievement, demonstrating that the technology has reached internationally advanced standards.”

    Prof. ZHANG Limin, CoProject Lead, National Engineer Awardee and Head of the Department of Civil and Environmental Engineering at HKUST, emphasized, “MUSICO’s observational coverage spans most land and ocean areas across low‑to‑mid‑latitude regions, providing consistent and comparable greenhouse gas monitoring data for different regions. The project’s results will be shared with government agencies and research institutions, supporting scientific research and practical applications in the Guangdong‑Hong Kong‑Macao Greater Bay Area and in other parts of China. They will also provide a scientific basis for cross‑regional climate research and emission reduction efforts along the Belt and Road, contributing to the global response to climate change. This is both a vivid example of HKUST’s research strength serving national strategy and a concrete practice of Hong Kong’s research capabilities contributing to global climate governance.”

    The research project is co‑led by Prof. SU Hui, Chair Professor of the Department of Civil and Environmental Engineering and Global STEM Professor at HKUST, and Prof. ZHANG Limin, Chair Professor and Head of the same department. Prof. ZHAI Chengxing, Associate Professor of the Division of Emerging Interdisciplinary Areas serves as the mission system engineer. Other team members include: Senior Scientific Officer Dr. RONG Pingping, Prof. ZHANG Jize, and Prof. WANG Zhe from HKUST’s Department of Civil and Environmental Engineering; Prof. NING Zhi, Prof. SHI Xiaoming, and Prof. GU Dasa from the Division of Environment and Sustainability; Prof. MA Xiaojuan from the Department of Computer Science and Engineering; Prof. ZHU Pengyu from the Division of Public Policy; Prof. GAO Meng from Hong Kong Baptist University; and Prof. LI Jia from Lingnan University.

    The project has also garnered strong industry support, including funding from HKUST-incubated startup Stellerus Technology Limited. Meanwhile, CLP Power Hong Kong Limited will collaborate with the project team to explore leveraging the data collected by MUSICO to complement its relevant assessments.

    Hashtag: #HKUST

    The issuer is solely responsible for the content of this announcement.

  • 全球首款轻小型高分辨率高精度二氧化碳与甲烷点源协同探测仪随天舟十号登「天宫」

    科大领衔研製 写下香港首项太空站科研载荷历史

    香港 – Media OutReach Newswire – 2026年5月13日 – 香港科技大学(科大)牵头研製的全球首款轻小型、高分辨率、高精度二氧化碳(CO₂)与甲烷(CH₄)点源协同探测仪「天韵相机」(Multi‑Spectral Imaging Carbon Observatory, MUSICO),于5月11日随天舟十号货运飞船顺利升空,并成功运抵中国「天宫」太空站。这不仅是香港首项登上国家太空站的科研载荷,更标志着香港在高端航天仪器研发领域实现历史性突破。此项目充分印证香港具备研製国家级世界先进水平的航天科研载荷的雄厚实力,能够参与太空站长期科学任务,并在应对全球气候变化、服务国家「碳达峰、碳中和」战略目标中发挥关键作用。

    该项目由科大研究团队领军,汇聚跨学科领域的专家学者,成员来自土木及环境工程学系、新兴跨学科领域学部、环境及可持续发展学部、计算机科学及工程学系,以及公共政策学部。项目于2024年底获中国载人航天工程空间应用系统总体单位——中国科学院空间应用工程与技术中心(空间应用中心)正式委托立项,并与中国科学院长春光学精密机械与物理研究所合作研製,同时获香港特别行政区政府创新科技署辖下创新及科技支援计划「特别征集(航天科技)」资助。

    MUSICO 是一套轻小型、高解析度、高精度的温室气体点源探测载荷,可从太空精准测量二氧化碳(CO₂)及甲烷(CH₄)两大主要温室气体。仪器体积比家用洗衣机更小,却能维持极高的光谱解析度及百米级空间分辨率。其原理是分析太阳光穿过大气层并经地表反射后的光谱变化,识别不同气体的吸收特征,从而计算浓度分布并锁定具体排放来源,可有效监测发电厂、堆填区等重点排放设施。

    香港特区政府创新科技及工业局局长孙东教授指出:「科大牵头的项目是香港首项进驻国家『天宫』太空站的科研载荷,为香港参与国家航天任务写下重要里程碑。国家『十五五』规划明确将加快绿色低碳转型、建设航天强国、推进碳达峰列为核心方向。香港科研团队自主研发的载荷成功在『天宫』开展任务,充分证明香港科学家在航天科技与绿色低碳前沿领域具备顶尖科研实力与成果转化能力,能够为国家提供高质量、可验证的科学数据,有力支撑国家加速实现双碳目标。」

    科大校长叶玉如教授表示:「科大研究团队能够参与国家太空站航天科研任务,我们深感荣幸,亦衷心感谢国家及香港特区政府长期以来的信任与支持。是次项目不仅充分彰显科大在航天与航空工程、卫星遥感及环境工程领域多年积累的科研优势,更证明香港科研力量有能力在国家最高层级的航天平台上作出实质贡献。MUSICO作为全球首款轻小型高精度温室气体点源探测载荷,未来将在国家太空站持续运作,为国家提供自主、可控、高可信度的二氧化碳与甲烷排放监测数据,直接服务于国家『碳达峰、碳中和』战略目标,并为『美丽中国』建设及全球气候治理提供科学支撑。」

    叶校长补充说:「科大近年持续深耕深空探测及低轨卫星技术——继2023年成功发射香港高等教育界首枚卫星后,亦积极参与国家『嫦娥八号』探月任务。未来,科大将继续发挥人工智能、机械人、材料科学等前沿领域的科研长处,加速推动科研成果转化与高端人才培育,为国家加快建设航天强国、实现绿色低碳高质量发展,贡献科大力量。」

    项目负责人、科大土木及环境工程学系讲座教授兼「杰出创科学人」苏慧教授表示:「MUSICO在研发中面临多项关键技术挑战——如何在严格的体积与重量限制下,同时兼顾高光谱解析度、高空间分辨率及多种温室气体的协同监测。团队在光学设计、精密加工、及系统整合等方面进行了大量测试与优化,确保仪器在高速运行及极端太空环境下,仍能长期提供可靠、精准的温室气体数据。将这些关键技术成功整合于一套轻小型载荷中,是一项具代表性的工程与科学成果,标誌着相关技术已达国际先进水平,也体现了科大在跨学科尖端科研上的核心竞争力。」

    另一项目负责人、「国家卓越工程师」兼土木及环境工程学系系主任张利民教授强调:「MUSICO的观测覆盖范围将涵盖地球大部分陆地与海洋的低至中纬度地区,为不同区域提供一致、可比的温室气体监测数据。项目成果将与政府部门和科研机构共享,有望支撑粤港澳大湾区乃至国家的科研需求,并为『一带一路』沿线国家和地区的跨地域气候研究与减排行动提供科学依据,助力国际社会共同应对气候变化。这既是科大科研实力服务国家战略的生动写照,也是香港科研力量贡献全球气候治理的具体实践。」

    研发项目由科大土木及环境工程学系讲座教授兼「杰出创科学人」苏慧教授,以及讲座教授兼系主任张利民教授共同领导;新兴跨学科领域学部副教授翟成兴教授担任项目系统工程师。其他团队成员包括科大土木及环境工程学系研究员荣平平、张纪泽教授和王者教授;环境及可持续发展学部宁治教授、石晓明教授和顾达萨教授;计算机科学及工程学系麻晓娟教授;公共政策学部朱鹏宇教授;香港浸会大学高蒙教授及岭南大学李佳教授。

    项目亦获得业界鼎力支持,包括得到科大孵化的星睿云智科技有限公司资助;同时,中华电力有限公司将与科大团队合作,探索运用「天韵相机」所采集的数据,以辅助其相关评估工作。

    Hashtag: #HKUST #科大

    The issuer is solely responsible for the content of this announcement.

  • Masterise Group Launches One Central Saigon

    Masterise Group Launches One Central Saigon

    Vietnam’s First Mixed-Use Landmark Destination

    Set opposite Ben Thanh Market, One Central Saigon is a landmark mixed-use destination where luxury living, hospitality, retail and business converge at the centre of Ho Chi Minh City. The project also marks The Ritz-Carlton hotel brand’s debut in Vietnam, alongside The Ritz-Carlton Residences, Saigon, Grade A+ offices, curated retail, services and fine dining.

    HO CHI MINH CITY, VIETNAM – Media OutReach Newswire – 13 May 2026 – Masterise Homes, a member of Masterise Group, has officially launched One Central Saigon, Vietnam’s first mixed-use landmark destination, marking the arrival of a new address where international standards of living, hospitality, retail, business and services come together in Ho Chi Minh City.

    One Central Saigon brings together The Ritz-Carlton, Saigon, The Ritz-Carlton Residences, Saigon, Grade A+ offices, curated retail, dining and lifestyle experiences in central Ho Chi Minh City.
    One Central Saigon brings together The Ritz-Carlton, Saigon, The Ritz-Carlton Residences, Saigon, Grade A+ offices, curated retail, dining and lifestyle experiences in central Ho Chi Minh City.


    The launch event was attended by representatives of Ho Chi Minh City government authorities, senior leaders from Masterise Group, Masterise Homes and Marriott International, as well as leading experts in real estate, economics and tourism.

    Over the past decade, the centre of gravity of the global economy has shifted decisively towards Asia, with Vietnam emerging as one of the region’s most compelling growth stories. Ho Chi Minh City, the country’s economic engine, is entering a new phase of development as a dynamic, deeply connected metropolis.

    Around the world, certain developments have helped shape how cities are recognised internationally, from Hong Kong’s IFC and Singapore’s Marina Bay Sands to Kuala Lumpur’s Petronas Twin Towers and Dubai’s Burj Khalifa. These projects did more than create striking skylines. They helped shape how the world sees their cities and countries. One Central Saigon is positioned within this tradition of city-shaping developments, with a vision that combines international standards, Vietnamese identity and long-term urban value.

    “We believe Vietnam has reached the moment where it is ready for a development of the calibre of One Central Saigon,” said Ms Nguyen Thi Minh Phuong, Managing Director, Southern Region, Masterise Group. “The project has been present in Ho Chi Minh City for some time and has passed through several phases of development. Today, it is being introduced with a clearer vision. With a sense of responsibility to contribute to the nation’s development journey in a new era, Masterise Group aspires to continue building an iconic landmark where the world’s highest experiential standards converge with the identity, energy and ambition of the city. This is also how we contribute to projecting the image of a modern, confident and culturally rich Vietnam onto the international stage.”

    A rare address in the city’s historic core
    For more than a century, Ben Thanh Market has been one of Ho Chi Minh City’s great urban constants: a place of trade, arrival and encounter, and one of the few landmarks instantly recognised across Vietnam and beyond.

    Its clock tower, market halls and surrounding streets are woven into the city’s daily rhythm and public memory, giving the area a significance that extends far beyond location. Set directly opposite the market, with four rare frontages along Pham Ngu Lao, Calmette, Le Thi Hong Gam and Pho Duc Chinh streets in the former District 1, One Central Saigon holds one of the city’s most strategic locations and shares a unique connection with Ho Chi Minh City’s historic urban core.

    One Central Saigon will rise as two towers above a retail and commercial podium on an 8,537 sqm site, with 19,990 sqm of commercial space across seven above-ground levels and six basement floors. The retail centre is envisioned as a destination for luxury retail, curated services and fine dining, with brands and experiences selected for both international appeal and the evolving needs of Vietnamese customers. Its basement levels will connect directly to Ben Thanh Metro Station via an underground link, integrating the project with the city’s public transit network.

    Together with Grade A+ offices, The Ritz-Carlton, Saigon and The Ritz-Carlton Residences, Saigon, the development forms a seamless mixed-use ecosystem for luxury living, hospitality, retail, business, services and lifestyle experiences at the centre of Ho Chi Minh City.

    Song Long Ngậm Ngọc: Vietnamese symbolism, global expertise
    The architecture of One Central Saigon is inspired by Song Long Ngậm Ngọc, or Twin Dragons Playing with a Pearl, a Vietnamese cultural motif associated with strength, prosperity and wisdom. The two towers rise and converge around a central point, creating a contemporary architectural expression of Vietnamese identity within the Ben Thanh district.

    Among the tallest twin towers in Vietnam and the region, One Central Saigon is a structurally complex undertaking that requires significant investment, precision, and attention at every stage of execution. The project brings together an international design and construction team, including Arquitectonica as design architect, HBA for interior design, B+H, a member of Surbana Jurong Group, as executive architect, and Turner for project management.

    International operational standards add another defining layer of value to One Central Saigon. With more than a century of heritage in luxury hospitality, The Ritz-Carlton brings refinement, attention to detail, privacy and highly personalised service to the project’s ultra-luxury positioning.

    The Ritz-Carlton Residences, Saigon opens a new chapter in ultra-luxury living, while The Ritz-Carlton, Saigon marks the hotel brand’s debut in Vietnam, reflecting Ho Chi Minh City’s growing appeal to international travellers, investors, entrepreneurs and high-net-worth individuals.

    The Grade A+ office component is designed for global corporations and forward-thinking business leaders seeking a workplace within a 5-star international ecosystem.

    Vietnam’s luxury momentum accelerates

    The launch comes as Vietnam continues to attract global capital, international brands and a rising generation of high-net-worth consumers. Official data showed real GDP growth of 8.02% in 2025, up from 7.09%, while foreign direct investment reached a record US$27.62 billion.

    Tourism is adding further momentum. Vietnam welcomed nearly 21.2 million international visitors in 2025, its strongest year for inbound tourism, while Ho Chi Minh City received nearly 8.6 million international visitors, up 40.3% year on year.

    Branded residences are following the same trajectory. Savills reports that branded residences in Asia Pacific increased by 55% over the past five years, while C9 Hotelworks’ Asia Branded Residences Market Review 2025 points to Vietnam as one of the region’s most important future supply markets.

    For Masterise Group, One Central Saigon extends an international branded real estate portfolio that includes Grand Marina, Saigon, featuring Marriott and JW Marriott-branded residences, and The Ritz-Carlton Residences, Hanoi at The Grand. It also gives Vietnam’s ultra-luxury real estate growth story tangible form beside one of Ho Chi Minh City’s most prized historical sites.

    As the city enters a new phase of development, expanding in both scale and quality, thoughtfully planned and professionally operated integrated developments such as One Central Saigon are expected to enrich the city’s tourism, services and urban experience ecosystem. The project is positioned to create lasting value for the community and elevate the standing of Ho Chi Minh City and Vietnam on the international stage.
    Hashtag: #MasteriseGroup

    The issuer is solely responsible for the content of this announcement.

    About Masterise Group

    Masterise Group is an international real estate development group, pioneering a comprehensive ecosystem spanning residential and hospitality developments, as well as urban infrastructure and logistics. Founded in 2007 as Thao Dien Investment and officially rebranded as Masterise Group in 2019, Masterise Group sees real estate as more than buildings; it is the foundation for a nation’s future, providing infrastructure for connection, momentum for progress, elevated living and generational legacy. With a long-term vision, Masterise Group continuously pushes boundaries, creates sustainable value, elevates quality of life and contributes to strengthening Vietnam’s new era of growth and global ambition.

    Masterise Homes is a member of Masterise Group and manages and develops all of the group’s residential real estate brands. As Vietnam’s pioneer in branded real estate development, Masterise Homes’ mission goes beyond delivering architectural landmarks with refined design and integrated amenities. Masterise Homes strives to craft comprehensive living spaces where residents experience a standard of living that goes beyond the basic function of a home.

    More info: .
    For images:

  • Bora Navigates A Transitional 1Q26 And Sets A Strong Foundation For Rest Of The Year

    Bora Navigates A Transitional 1Q26 And Sets A Strong Foundation For Rest Of The Year

    Transformational Acquisitions Expected to Contribute to Long Term Growth Starting 2Q26

    HONG KONG SAR – Media OutReach Newswire – 13 May 2026 – Bora Pharmaceuticals (“Bora”; TWSE: 6472; OTCQX: BORAY) today announced its financial results and operational highlights for 1Q2026 and provides full year outlook.

    1Q26 Business and Financial Highlights

    • The Company reported 1Q26 revenues of NT$4,001 million, down 17.68% sequentially, with basic EPS of NT$0.21. Gross margin stabilized quarter-over-quarter. The quarter reflected temporary slowdown across both businesses: pricing and demand variability in the generics market through January and February left Upsher-Smith’s 1Q26 revenue 18.63% below the trailing four-quarter run rate, while the scheduled annual maintenance of 6 weeks of our Maryland fill-finish facility limited fixed-cost absorption during the quarter, weighed on earnings quality.
    • March saw a rebound in both businesses as conditions improved for both the top and bottom lines with steady demand. During the quarter, the Company advanced Maple Grove site ramp-up significantly, with several multi-year CDMO agreements signed or progressing across pharma clients of various sizes. Additionally, the Company continues to win new CDMO business as 12-month rolling backlog arrived at US$315 million. With a healthy order book at North American sites entering the second quarter, we expect fixed-cost leverage to resume, driving profit improvement as utilization builds across the installed asset base. Meanwhile, Upsher-Smith has successfully defended market share and is deploying lifecycle management initiatives that reinforce our ability to set the cadence of sales in a dynamic competitive environment.
    • Non-operating loss primarily reflected a wider equity loss from affiliate Tanvex Biopharma, together with higher tax expense driven by annual 1Q recognition of tax from undistributed earnings of the previous year.
    • Disciplined OPEX control has driven expenses down 14.87% quarter-over-quarter and 14.41% year-over-year. This signals that resources have settled in as we begin to see advantages in scale; The Company expects ROA and ROIC to trend gradually upward, albeit with some quarter-to-quarter variability as operating leverage builds.
    • Board of Directors approved the acquisition of the CDMO business of MacroGenics Inc. (NASDAQ: MGNX), for total consideration of US$122.5 million, leading to a total 12-month rolling backlog upon closing to approximately US$375 million.
    • Sunway Biotech’s Board approved the 100% acquisition of Weider Global Nutrition (“WGN”), an iconic Phoenix-based American sports nutrition brand with a strategic Costco U.S. supplier relationship, commercial presence in 60+ countries, and established positions on Amazon and Walmart. The transaction completes Bora Group’s three-platform architecture, namely CDMO, pharma sales, and nutraceuticals operated under our “dual engine” strategy.
    • Share capital increased 0.04% during the quarter from employee stock option exercise.


    Mr. Bobby Sheng, Chairman of Bora Group, stated, “The beginning of 2026 was eventful and challenging both in the world and at Bora. We have seen supply chain disruptions, inflation from wars, and continuous geopolitical tensions. Yet through it all, Bora Group’s disciplined approach to growth-oriented investment remained unwavering.

    Our CDMO business CAPEX-to-revenue ratio reached an all-time high of over 10% in 2025, marking another year of upward progression and bringing the Company to a level comparable with established global CDMO peers. This marked a deliberate shift in where we direct investments from capacity-led expansion that defined our earlier growth chapters to a sharper focus on capability demands and modality, anchored in innovation and technology. Over the past 18 months, we have pursued an ambitious growth trajectory against a dynamic macroeconomic backdrop – recalibrating expectations, sharpening our strategy, and reaffirming long-term plans. The underlying demand environment supports our conviction: global pharma is growing at 5-8% per year, biologics CDMO outsourcing demand at 15%+ and small-molecule outsourcing demand at 8-10%. With our investment foundation now in place, we believe our CDMO business is positioned to compound organically at 13-23% annually.

    In the first quarter, we executed a series of organizational adjustments, each aligned to a specific dimension of customer demand. We established the MSAT (Manufacturing, Science and Technology) function within the CDMO business, the R&D backbone of the platform, to deepen scientific and technical capability across our entire client base, an increasingly critical asset as small and mid-sized biotech and pharma clients rethink their supply chain. In parallel, we repurposed the Strategic Enterprise Account Management team into a networked model to serve clients for whom customer proximity is paramount. Together, these capability investments target specific customer pain points and position Bora to navigate the evolving political and economic landscape and capture a new chapter of commercial momentum.

    To sum up, CDMO business in 1Q26 delivered US$27.2 million in total external wins on top of orders on hand, 60% or 7 molecules from pre-commercial programs. For context, full-year 2025 saw 16 pre-commercial molecule signings; 1Q26 alone has already secured nearly half that count in a single quarter. This run-rate acceleration is a leading indicator: as our capability investments take hold, forward visibility and growth potential are set to compound. Bora’s CDMO business has entered a new phase. Reinforcing this trajectory, the Group’s recently announced acquisition of MacroGenics’ Rockville, Maryland CDMO facility adds a substantial commercial-stage monoclonal antibody programs backlog and manufacturing expertise to the Group. Equipped with five 2,000-liter and two 500-liter single-use bioreactors and integrated QC and analytical labs and currently generating more than half of revenues from commercial manufacturing, the transaction marks a pivotal step in scaling Bora’s integrated biologics CDMO platform, known as Bora Biologics. DS and DP capabilities shall be integrated over the next 12–18 months to offer global biotech customers a single partner from development through commercial supply in the U.S..

    On the pharma sales side, the Group faced competition across a handful of core generic products. Upsher-Smith is navigating the competitive landscape with a clear focus on the most margin-accretive opportunities while continuing to scout niche, brand-oriented assets. Near-term, DLS market share has been defended; over the medium term, sustained market share maximization of the infantile spasm franchise coupled with swift pipeline replenishment weighted toward differentiated assets is critical. In the first quarter, we saw unique patients for VIGAFYDE grew by more than 140% over same period last year and a continuous increase in new patients. Both healthy signs of steady execution pace building up to durable resilience in the pharma sales business.”

    1Q26 Operational Achievements & 2026 Outlook


    Global CDMO Operations

    Revenues declined 24.62% year-over-year and 30.15% quarter-over-quarter including internal orders, mainly due to above-mentioned maintenance at fill and finish facility in Maryland, a routine cycle factored into our operating plan, and seasonality at Canada site. To scale biologics CDMO one-stop-shop platform in commercialized projects with SUB (Single Use Bioreactors) in the US; Board of Directors approved the acquisition of Rockville, Maryland based drug substance facility from MacroGenics for US$122.5 million.

    Following closing, Bora Group intends to leverage the Rockville Site in cooperation with Tanvex Biopharma (TWSE: 6541), which operates the Group’s biologics CDMO franchise under the “Bora Biologics” brand. Together with Bora’s sterile drug product capabilities, this is expected to expand and strengthen the Group’s end-to-end biologics platform. The Rockville facility has operated as an outsource manufacturing partner since 2022 and is equipped with five 2,000-liter and two 500-liter single-use bioreactors and fully integrated QC and analytical laboratories and has been inspected by both the U.S. FDA and Japan’s PMDA.

    During the quarter, 0.44 billion doses, or 108 molecules, were developed and manufactured. Excluding internal orders, the business accounted for 37.73% of consolidated revenues. Contribution from the top 20 global pharmaceutical companies stood at 32.10%.

    As the Company continues to expand its CDMO capacity and capabilities, this year’s CAPEX plan is closely linked to the contracting cadence of a key customer anchored at Bora’s North American CDMO network. The Group expects to complete Maple Grove’s capital expenditure program in the first half of the year, sequencing the investment to grow in step with major pharmaceutical partners’ supply chain plans and optimize return on capital deployed.

    Pharma Sales Operations

    Discontinued operations impact in 2025 has materially abated this quarter, positioning Upsher-Smith to re-accelerate organic growth in 2026. Management has defined two strategic priorities for 2026, designed to enhance capital efficiency and sharpen commercial focus:

    First, R&D capital allocation optimization. 505(b)(2) Pipeline programs have been transferred to Salus Therapeutics, an equity-method affiliate. Under this structure, Upsher-Smith retains the right to economic participation in commercial outcomes while shareholders’ exposure to early-stage development and regulatory risks, and associated cash burden is meaningfully reduced. The decision is consistent with the Group’s capital discipline observed across businesses.

    Second, institutionalizing pipeline expansion capabilities. An integrated business development and medical affairs function is being established to systematically evaluate in-licensing, co-promotion, and bolt-on opportunities. This integrates Bora’s proven asset-selection and M&A strategy directly into Upsher-Smith’s commercial infrastructure, enabling franchise compounding through targeted external sourcing rather than capital-intensive internal development. These lifecycle initiatives focus but are not limited to pediatric epilepsy opportunities.

    Collectively, Management expects Upsher-Smith to evolve fully into a capital efficient, commercially led, and therapeutically centered vehicle designed to deliver sustained shareholder value before exiting 2026.

    Recent Investor Conference

    Bora will host English online earnings call at 7:30 a.m. Taiwan time on May. 14th, 2026. The event will cover the Company’s 1Q26 financial and business results and 2026 outlook.

    English Online Earnings Presentation Link: https://events.q4inc.com/attendee/372103448

    Bora will participate in 2026 Yuanta Securities Investment Forum in June. For 1:1 meetings with management, please contact your Yuanta representative.

    Bora 2026 Earnings Schedule

    Q2 2026: Expected in the 2nd week of Aug 2026
    Q3 2026: Expected in the 2nd week of Nov 2026
    Q4 2026: Expected in the 2nd week of Mar 2027

    Hashtag: #BoraPharmaceuticals

    The issuer is solely responsible for the content of this announcement.

    About Bora

    Founded in 2007, Bora Pharmaceuticals (“Bora” or “the Company”, 6472.TW and BORAY.OTCQX) is a leading pharmaceutical services company with a vision and goal of “Contributing to Better Health All Over the World”. Operating under a “Dual Engine” model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients’ quality of life.

    By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. Committed to making success “certain,” Bora sets new standards in the pharmaceutical and CDMO industries.

    For more, please visit:

    Disclaimer:

    This document and the accompanying information may contain forward-looking statements. All statements regarding the company’s future business operations, potential events, and prospects (including but not limited to forecasts, targets, estimates, and operational plans) are considered forward-looking statements unless they refer to factual occurrences. Forward-looking statements are subject to various factors and uncertainties that may cause significant differences from actual results, including but not limited to price fluctuations, actual demand, exchange rate variations, market share, competitive conditions, changes in the legal, financial, and regulatory framework, international economic and financial market conditions, political risks, cost estimates, and other risks and variables beyond the company’s control. These forward-looking statements are based on current predictions and assessments, and the company disclaims any responsibility for future updates.

  • 保瑞公佈2026年首季財務報告

    保瑞公佈2026年首季財務報告

    走過充滿挑戰的第一季,保瑞預期近期併購建立新的穩健根基 重啟策略投資驅動CDMO下一篇章

    香港 – Media OutReach Newswire – 2026年5月13日 – 全球領先的CDMO及專科製藥公司——保瑞藥業股份有限公司(Bora Pharmaceuticals,「保瑞」;TWSE:6472;OTCQX:BORAY)今日公布2026年第一季財務成果與營運亮點,並提供2026年展望。

    2026年第一季營運與財務重點:

    • 第一季合併營收為新台幣40.01億元,季減17.68%,每股盈餘為0.21元,毛利率與上季相比持穩。本季度中雙引擎事業體所面臨的階段性逆風包括學名藥市場於1至2月出現價格與需求波動,致使Upsher-Smith營收較最近四季平均下滑18.63%,以及馬里蘭州無菌針劑廠依計畫進行為期六周的半年度檢修,無菌針劑廠固定成本較高使得獲利承壓。
    • 3月起,營收與獲利均回穩。除了美國Maple Grove廠在第一季中接單動能顯著提升,CDMO業務接單動能強勁,未來12個月在手訂單增加至3.15億美元,在手訂單能見度良好,預期營運槓桿隨產能利用率提升將重新發酵。此外,Upsher-Smith 已成功守住旗艦學名藥產品DLS市占率,並持續推動產品生命週期管理,於高度變動的競爭環境中掌握銷售節奏,復甦動能逐步浮現。
    • 本季業外表現主因認列權益法投資之泰福生技虧損擴大而呈現負數;所得稅費用上升則主要來自第一季慣例認列之未分配盈餘加徵所得稅。
    • 營業費用季減14.87%、年減14.41%,反映資源配置在內外波動後已趨最適狀態,部分廠區與產品線已具經濟規模效益。公司預期ROA與ROIC將逐步回穩,惟單季間仍會有所波動,整體將隨營運槓桿持續釋放而向上。
    • 董事會於日前通過以總對價1.225億美元收購美國上市公司MacroGenics Inc.(NASDAQ:MGNX)旗下CDMO業務;交易完成後,預期在手訂單將提升至約3.75億美元。
    • 旗下晨暉生技董事會通過以100%股權收購Weider Global Nutrition(「WGN」);該品牌公司總部設於美國鳳凰城,為全球指標性運動營養品牌,與美國大賣場Costco具策略性供應商關係,業務遍及60餘國,並有Amazon、Walmart等穩定銷售據點。本案除了挹注集團事業規模,CDMO、全球市場銷售、保健品三大事業也完成最後一塊拼圖。
    • 本季因員工認股權證行使,股本增加0.04%。

    保瑞集團董事長盛保熙表示:「2026年開春以來對國際局勢或保瑞自身都是一個充滿變化與挑戰的季度。供應鏈仍有干擾、戰爭引發的通膨持續、地緣政治張力未減。但在這樣的環境之下,保瑞集團遵守投資紀律、持續投注資源帶動成長的堅持並未動搖,2024與2025年接連創下CDMO業務資本支出占營收比重新高,截至去年來到約10%,是與國際CDMO同業幾近可比的投入。保瑞在變動中因應市場需求優化了投資方向,從早年定義成長軌跡的『產能擴張型』投資,轉向以技術為核心的『能力與劑型布局』投資;過去18個月,我們總體經濟波動中持續推進成長策略,並在過程中重新校準預期、聚焦團隊。

    CDMO業務方面,2026年是策略性投資開啟新篇章的關鍵年。第一季我們完成回應特定的客戶需求面向的組織與服務升級。我們在CDMO事業體內成立MSAT(Manufacturing, Science and Technology)團隊作為研發核心,深化全客戶層級的科學與技術能力;保瑞相信此一能力於現階段至關重要:在募資環境逐步回溫但仍受限的氛圍下,中小型生技與製藥客戶受在地化製造政策推動需重新檢視供應鏈布局。同時,我們將企業客戶管理團隊優化為網絡式架構,滿足近距離支援客戶的需求。上述布局精準切入客戶痛點,使保瑞具備在動盪的政經環境中開創新一波商業動能的能力。

    整體而言,CDMO業務截至三月底在既有在手訂單之外,再新增了2,720萬美元外部新案,其中60%(即7個分子)來自臨床前及臨床階段專案。對照之下,2025全年共簽下16個臨床前與臨床階段分子,第一季單季已達該全年數字的近半。此一節奏加速為前瞻性指標:隨著軟實力的投資逐步發酵,業務能見度與成長潛力將持續釋放。

    我們很驕傲地宣布保瑞CDMO事業已邁入新階段。日前,保瑞董事會通過收購美國MacroGenics公司位於馬里蘭州Rockville之CDMO廠,是此階段的第一頁;該交易為集團帶來龐大的商業階段單株抗體在手訂單與深度製造專業。該廠配備5座2,000公升及2座500公升單次性使用生物反應器,並具備整合之QC與分析實驗室,目前商業化生產佔營收過半。本案標誌著保瑞於美國市場打響生物製劑CDMO平台『Bora Biologics』的大步邁進,集團將在未來12-18個月整合內部DS能量與DP網絡,向全球生技客戶提供單一窗口之全流程服務,更有效率地回應打造美國供應鏈韌性的藥品市場期待。

    我們相信業務將隨著生技製藥委外代工市場的增長潛力增長而起飛:全球生技製藥市場總體以5-8%的年增率拓展,而生物製劑委外代工增速更快,達15%,小分子委外代工亦有高於產業平均的8-10%,截至目前的投資可望帶來未來數年13-23%的有機增長。

    本季全球市場銷售業務仍面臨核心學名藥產品競爭的挑戰,使得產品組合轉差,經過一個季度的攻防,Upsher-Smith將聚焦最有獲利潛力的機會,同時持續尋覓利基型品牌資產布局。短期而言,DLS市占率已成功守穩;中期而言,持續拓展嬰兒點頭式痙攣症產品線市占,搭配發展差異化資產,快速補強藥品產品線將是關鍵成功要素。第一季中,VIGAFYDE的不重覆患者數(Unique Patient)較去年同期增加超過140%,新病患數亦穩定攀升,兩者都是建構中長期韌性的健康指標,可望穩定獲利曲線。」

    2026年第一季營運成果暨2026年展望

    業務進展說明:

    – 全球委託研發暨代工製造服務(Global CDMO Operations)業務
    受馬里蘭無菌針劑廠依計畫進行為期六周的半年度檢修時程以及加拿大廠進入淡季影響,全球CDMO業務含內部訂單之營收年減 24.62%、季減 30.15%;為持續推進生物製劑CDMO在美的一次性生物反應槽產能平台,集團董事會通過以美金1,225億元收購位於馬里蘭州Rockville之生物藥原料廠。

    保瑞規劃於交割時將Rockville廠的營運依據集團的專業分工與泰福生技合作,以集團大分子專業分工,加速整合泰福生技聖地牙哥廠、保瑞CDMO業務的馬里蘭州針劑廠及此Rockville廠三位一體的戰略角色,進一步於國際間打響Bora Biologics的聲望;輔以專精於前期開發的泰福台灣竹北廠,此項投資可望大幅提升保瑞集團在全球市場的生物藥委外研發製造格局。

    Rockville廠自2022年起投入CDMO業務,配備5座2,000公升及2座500公升之一次性生物反應槽(single-use bioreactors),以及完整的品管與分析實驗室,皆已通過美國FDA與日本PMDA查核。
    本季CDMO業務共開發及生產4.4億劑藥品、共108個分子。不含內部訂單,CDMO業務占合併營收 37.73%;全球前20大製藥公司營收貢獻32.10%。
    隨公司持續擴展CDMO產能與技術布局,本年度資本支出計畫與保瑞北美CDMO網絡所定錨之關鍵客戶簽約節奏密切連動。集團預期於上半年完成Maple Grove廠資本支出計畫,並依大型製藥合作夥伴之供應鏈規劃調整投資節奏,以最大化資本部署之投資回報。

    – 全球市場銷售(Global Commercial Operations)業務

    2025年停業部門拖累於本季顯著消退,Upsher-Smith已具備重啟有機成長的條件。管理層已為2026年訂出二項策略優先事項,旨在提升資本效率、聚焦商業重心:
    第一,研發資本配置最適化。505(b)(2)新藥研發專案已移轉至權益法持有之轉投資保豐生技,Upsher-Smith仍保有未來商業化成果的經濟參與權,但保瑞股東於早期研發及法規風險的曝險以及伴隨之資金消耗皆顯著降低。此一決策符合集團於各事業體一貫的資本紀律方針。
    第二,產品線擴張策略體制化。Upsher-Smith已整合業務開發與醫藥事務團隊,以系統性方式評估授權引進、共同推廣及補強型併購機會。此舉將保瑞既有之選題與併購策略基因直接導入Upsher-Smith的商業平台,透過外部資源整合驅動產品線的複利成長,取代資本密集的內部研發路徑。相關生命週期管理布局將以小兒癲癇領域與罕病領域為核心,但不限於此。
    整體而言,管理層預期Upsher-Smith將於2026年完成轉型,成為一具備資本效率、商業化導向、並深植於特定治療領域的藥品公司,為股東持續創造長期價值。

    年度營運報告及法說會資訊

    保瑞將在台灣時間5月14日上午7:30舉辦英文線上業績發表會,向投資人說明公司2026年第一季財務與業務報告及展望。
    英文線上業績發表會連結:https://events.q4inc.com/attendee/372103448

    保瑞2026年業績報告行事曆

    2026年第2季:預計2026年8月第二周
    2026年第3季:預計2026年11月第二周
    2026年第4季:預計2027年3月第二周

    Hashtag: #BoraPharmaceuticals #保瑞

    The issuer is solely responsible for the content of this announcement.

    關於保瑞

    保瑞藥業股份有限公司(股票代碼:6472)成立於2007年,是一家領先的製藥服務公司,自成立伊始即秉持「為全世界健康貢獻力量」的願景與目標。保瑞以整合 CDMO(委託開發與製造服務)與藥物開發銷售的「雙引擎」商業模式,協助製藥與生技合作夥伴優化產品開發流程、加速上市時程、擴大供應規模以滿足全球患者的需求。公司亦專注於美國的利基市場及罕見疾病領域,致力於透過拓展銷售通路實力提升患者的生活品質。

    透過持續投資人才、生產與銷售及進入生物製劑業務領域,保瑞不斷推動業務升級與永續發展,專注高品質、高效率與可靠性,在製藥及 CDMO 領域樹立新標杆。

    請造訪:企業網站

    免責聲明:

    本文件及同時發佈之相關資訊內可能含有預測性敘述。除針對已發生之事實,所有對於本公司未來營運業務、可能發生之事件及展望(包括但不限於預測、目標、估算及營運計畫)之敘述皆屬預測性敘述。預測性敘述會受不同因素及不確定性之影響,造成與實際情況有相當差異,這些因素包括但不限於價格波動、實際需求、匯率變動、市佔率、市場競爭情況、法律、金融及法規架構的改變、國際經濟暨金融市場情勢、政治風險、成本估計等,及其他本公司控制範圍以外的風險與變數。這些預測性敘述是基於現況的預測和評估,本公司不負日後更新之責任。

  • Esperanza Partners with One Cool Stage to Open New Financing Frontiers for Hong Kong’s Cultural Assets Esperanza

    Esperanza Partners with One Cool Stage to Open New Financing Frontiers for Hong Kong’s Cultural Assets Esperanza

    Hong Kong theatre IP “The Big Big Day” anchors the next phase of fan participation and entertainment asset tokenization, with qualifying projects potential exceeding HK$2 billion in scale

    HONG KONG SAR – Media OutReach Newswire – 13 May 2026 – Esperanza Fintech (Securities) Limited (“Esperanza” or the “Company“) is pleased to announce that a tokenized fund managed by the Company has participated in co-presenting The Big Big Day (《大龍鳳》), a Hong Kong theatre IP project produced by One Cool Stage Limited (“One Cool Stage“), a subsidiary of One Cool Group Limited. A cooperation arrangement to this effect has been signed by both parties. The collaboration marks a further extension of Esperanza’s regulated fintech solutions — building on its earlier tokenized live-entertainment offerings — into Hong Kong theatre, cultural IP, and fan-engagement scenarios, as the Company continues to explore the commercial value and applications of cultural and entertainment assets under new financing models.

    One Cool Group Limited is one of Hong Kong’s most recognizable integrated film and entertainment enterprises, with operations spanning film, television, production, post-production, artist management, and related entertainment services. The partnership with One Cool Stage not only reflects Esperanza’s continued expansion of tokenization use cases for cultural and entertainment assets, but also showcases the broader development potential of high-quality Hong Kong content and IP under new financing frameworks.

    As a Hong Kong-based fintech and real-world asset (RWA) tokenization platform serving the Asia-Pacific market, Esperanza is committed to operating within a regulated framework to connect quality assets, professional investors, content owners, project operators, and fan communities — building more transparent, participative, and scalable financial infrastructure for cultural and entertainment projects.

    Mr. Ronald Leung, Group Chief Executive Officer and Chief Legal Officer of Esperanza, said:

    “The Big Big Day project is more than a single theatre collaboration — it represents another important milestone in Esperanza’s work to bring tokenized capital solutions to Hong Kong’s cultural and entertainment assets. Hong Kong has long stood at the intersection of Asian culture, creativity, and capital. We see this city as the ideal starting point for combining high-quality local content with next-generation fintech infrastructure, and for forging deeper value linkages among content owners, project parties, fan communities, and professional investors. As part of this project, Esperanza will also take the lead in launching tokenized experience applications in Hong Kong, enabling supporters to participate in ticket redemption, exclusive merchandise offerings, and cultural entertainment experiences through relevant tokenized arrangements. This will further extend the interaction between stage productions and audiences beyond the performance itself. Through compliant tokenization solutions, Esperanza will continue to support more projects of cultural significance and market potential in establishing financing connections that are more flexible, more transparent, and more participatory.”

    Ms. Ella Wong, Chief Financial Officer of One Cool Group Limited, said:

    “We are delighted to begin this collaboration with Esperanza. In today’s diversified entertainment ecosystem, innovation in financial structuring is critical to advancing the creative industries. Through this partnership, we look forward to leveraging professional fintech infrastructure and solutions to open up more flexible commercial possibilities for Hong Kong’s cultural and entertainment assets.”

    This collaboration also reflects Esperanza’s continued strategic build-out in entertainment and cultural assets. The Company is actively sourcing additional projects with tokenization potential and commercial scalability — across film, live entertainment, theatre IP, licensing businesses, AI-driven immersive entertainment, multimedia applications, experiential venues, and other categories underpinned by real-asset foundations and commercial cash flow potential.

    As Asia-Pacific’s content industries, fan-engagement models, AI technologies, and immersive entertainment ecosystems continue to evolve rapidly, Esperanza expects growing market demand for mature, compliant financial platforms capable of helping high-quality cultural and entertainment projects expand their access to capital, community engagement, and commercialization capabilities. The Company is currently evaluating and progressing multiple related opportunities, with a potential project pipeline expected to exceed HK$2 billion in scale across entertainment and culture, IP licensing, real estate, multimedia, AI immersive entertainment, and other real-world asset applications.

    Esperanza emphasizes that the Company will continue to anchor its work in compliance, transparency, and sustainability — guiding cultural and entertainment assets from traditional project financing and single-consumption models toward more institutionalized, digitalized, and participatory new financing markets, and creating new growth opportunities for Hong Kong and the wider Asia-Pacific creative industries.

    Hashtag: #Esperanza

    The issuer is solely responsible for the content of this announcement.

    About Esperanza Fintech (Securities) Limited

    Esperanza Fintech (Securities) Limited (“Esperanza“) is a licensed corporation under the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong), permitted to carry on Type 4 (advising on securities) and Type 9 (asset management) regulated activities. On 13 February 2026, Esperanza received a “no further comment” letter from the Hong Kong Securities and Futures Commission in respect of its proposal to tokenize managed funds — formally permitting Esperanza to conduct tokenized investment business.

    About One Cool Stage Limited

    One Cool Stage Limited (“One Cool Stage“) is a subsidiary of One Cool Group Limited, engaged in the development of cultural, entertainment, and theatre projects in Hong Kong. Founded in 2013 and headquartered in Hong Kong, One Cool Group Limited is a diversified enterprise dedicated to the development of the film and entertainment industry. Guided by the philosophy of “Visionary in Creativity, Strive for Diversity,” the Group has built a multi-faceted business portfolio spanning the entire entertainment industry value chain, with stable partnerships and operational footprints across major Asian markets. For more information, please visit .

    About Esperanza Fintech Group

    Esperanza Fintech Group is a fintech group headquartered in Hong Kong. The group’s licensed businesses include (i) gold trading and tokenized gold services operated by Esperanza Fintech (Commodities) Limited, a DPMS (dealers in precious metals and stones) Category A Registrant (No. A-B-25-03-08913) with the Hong Kong Customs with permitted businesses including the issuance, redemption and trading of gold backed instruments on ; (ii) client asset custodian service operated by Esperanza Fintech (Nominees) Limited, a licensed Trust or Company Service Provider in Hong Kong (Licence No. TC010260), regulated by the Hong Kong Companies Registry; (iii) espetopia trading platform operated by Espetopia Limited; and (iv) tokenized investment services operated by affiliate company Esperanza Fintech (Securities) Limited, an SFC-regulated asset manager with permission to carry out tokenized investment businesses.

  • LGT appoints CEO for its wealth management business in Thailand

    LGT appoints CEO for its wealth management business in Thailand

    BANGKOK, THAILAND – Media OutReach Newswire – 13 May 2026 – LGT continues to strengthen its leadership team in Thailand with the appointment of Anchalee Bunsongsikul as Chief Executive Officer of LGT Securities (Thailand) Limited (“LGT Thailand”). This senior management hire underlines the strategic importance of Thailand for LGT and reflects the firm’s commitment to further expanding its presence in the market.

    Anchalee Bunsongsikul
    Anchalee Bunsongsikul

    With over three decades of leadership experience in international banking, including most recently as President and Chief Executive Officer, Thailand and Representative Offices for Standard Chartered Bank, Anchalee Bunsongsikul will further strengthen LGT’s senior management bench in Thailand. She brings extensive experience in corporate banking, financial markets and client coverage, as well as a deep understanding of the local client landscape.

    Commenting on the appointment, Dr. Henri Leimer, Chief Executive Officer, LGT Private Banking Asia Pacific, said: “Thailand is an important market for us, one where we have built a strong market position through a consistent, relationship-led approach focused on serving Thai families and entrepreneurs.” Karn Karuhadej, Managing Director and Senior Market Adviser, added: “Anchalee brings extensive leadership experience, strong client relationships and deep market knowledge that will further strengthen our franchise in Thailand. We look forward to welcoming her to our team and working together to further develop our business in the region.”

    The appointment will take effect on 15 May 2026. Upon joining LGT Thailand, Anchalee Bunsongsikul will also become a member of the Executive Board Asia Pacific of LGT Private Banking.

    LGT has deep roots in Asia. Since opening its first representative office in Hong Kong in 1986, LGT has grown into a competitive regional private bank and wealth manager. In 2019, LGT launched its wealth management business in Thailand. Today, the Bangkok office comprises a strong team of experienced relationship managers and investment consultants who provide investment and wealth management services to Thai clients, complementing LGT’s private banking operations in Hong Kong and Singapore.

    Across Asia Pacific, LGT has a presence in Hong Kong, Singapore, Thailand, Japan, Australia, India and the Middle East, and employs around 1800 people in the region. In 2025, LGT ranked as the sixth1 largest private bank in the region, with USD 164 billion in assets under management as of the end of 2025.


    1Based on finews.asia 2025 Private Banking AUM league table (finews.asia Releases 2025 Private Banking AUM League Table)

    Hashtag: #LGT

    The issuer is solely responsible for the content of this announcement.

    LGT in brief

    LGT is a leading international private banking and asset management group that has been fully controlled by the Liechtenstein Princely Family for over 90 years. As at 31 December 2025, LGT managed assets of CHF 386.1 billion (USD 487.3 billion) for wealthy private individuals and institutional clients. LGT employs 6000 people who work out of more than 40 locations in Europe, Asia, the Americas, Australia and the Middle East. .

  • Esperanza 携手天下一幕,拓展香港文化资产新金融

    Esperanza 携手天下一幕,拓展香港文化资产新金融

    以《大龙凤》为剧场 IP 案例,连接粉丝参与与娱乐资产代币化应用,潜在项目储备规模预计逾港币20亿元

    香港 – Media OutReach Newswire – 2026年5月13日 – 毅盛金融科技(证券)有限公司(「Esperanza」或「公司」)欣然宣布,旗下管理的代币化基金参与协办天下一幕有限公司(「天下一幕」)旗下的香港本地剧场 IP 项目《大龙凤》,双方已就此签署合作安排。 天下一幕为天下一集团旗下子公司。 是次合作标志着Esperanza继早前娱乐演出代币化项目后,进一步将其合规金融科技方案延伸至香港剧场、文化IP及粉丝参与场景,持续探索文化娱乐资产于新金融模式下的商业价值与应用潜力。

    天下一集团为香港具代表性的综合影视娱乐企业,业务涵盖电影、电视、制作、后期制作、艺人管理及相关娱乐产业服务。 是次与天下一幕的合作,不仅反映Esperanza持续拓展文化娱乐资产代币化应用场景,亦展示香港本地优质内容及IP项目在新金融模式下的更多发展可能。

    作为立足香港、面向亚太的金融科技及真实世界资产代币化平台,Esperanza致力于在合规框架下,连接优质资产、合资格投资者、内容持有人、项目营运方及粉丝社群,为文化娱乐项目建立更具透明度、参与度及延展性的金融基础设施。

    Esperanza 集团行政总裁兼首席法务官梁卫晋表示:

    「《大龙凤》项目不单是一个剧场合作,更是 Esperanza 在香港文化娱乐资产金融化领域的另一个重要实践案例。 香港一直是亚洲文化、创意及金融交汇的重要城市,我们希望以香港作为起点,将本地优质文化娱乐内容与新型金融科技工具结合,推动内容持有人、项目方、粉丝社群及合资格投资者之间形成更深层次的价值连结。 在本项目中,Esperanza亦将于香港率先推出代币化体验应用,让支持者可透过相关代币化安排,参与门票兑换、专属周边及文化娱乐体验消费,进一步延伸舞台作品与观众之间的互动关系。 透过合规代币化方案,Esperanza将持续协助更多具文化价值及市场潜力的项目,建立更灵活、更透明及更具参与感的新金融连接模式。」

    天下一集团首席财务官黄詠茵表示:

    「我们很高兴能与 Esperanza 团队展开合作。 在现今多元化的娱乐产业生态中,财务架构的创新对于推动创意产业发展至关重要。 透过这次合作,我们期待能运用专业的金融科技工具方案,为香港文化娱乐资产开拓更灵活的商业可能。」

    是次合作亦反映Esperanza在娱乐及文化资产领域的持续布局。 公司正积极发掘更多具备代币化潜力及商业延展性的项目,涵盖电影、现场娱乐、剧场IP、授权业务、AI沉浸式娱乐、多媒体应用、体验式场景,以及其他具备真实资产基础及商业现金流潜力的项目类别。

    Esperanza预期,随着亚太区内容产业、粉丝参与模式、人工智能技术及沉浸式娱乐生态快速发展,市场将需要更成熟的合规金融平台,协助优质文化娱乐项目拓展资本连接、社群参与及商业化能力。 目前,公司正评估及推进多个相关项目,潜在项目储备规模预计逾港币20亿元,涵盖娱乐文化、授权IP、物业、多媒体、AI沉浸式娱乐及其他真实世界资产应用方向。

    Esperanza强调,公司将继续以合规、透明及可持续发展为核心,推动文化娱乐资产由传统项目融资及单一消费模式,逐步走向更制度化、数字化及具参与性的新金融市场模式,为香港及亚太区创意产业创造新的增长空间。

    Hashtag: #Esperanza

    The issuer is solely responsible for the content of this announcement.

    关于毅盛金融科技(证券)有限公司

    毅盛金融科技(证券)有限公司(「Esperanza」或「公司」)证券为一家根据证券及期货条例(香港法例第571章)获发牌的公司,获许可进行第四类(就证券提供意见)及第九类(提供资产管理)业务。 Esperanza 于2026年2月13日获香港证监会确认对Esperanza 就其管理的基金进行代币化一事并无进一步意见,即正式准许Esperanza 进行证券代币化业务。

    关于天下一幕有限公司

    天下一幕有限公司(「天下一幕」)为天下一集团旗下公司,参与香港文化娱乐及剧场项目发展。 天下一集团成立于2013年,总部设于香港,是一家致力于电影与娱乐产业发展的综合企业。 本着「创新视野‧敢作敢为」的宗旨,集团建立横跨整个娱乐产业价值链的多元业务版图,并于亚洲主要市场建立稳定合作及业务布局。 欲了解更多信息,请浏览官网

    关于Esperanza金融科技集团

    Esperanza金融科技集团是一家以香港为总部的金融科技公司。 集团持牌业务包括(i)营运黄金交易及代币化黄金的毅盛金融科技(商品)有限公司(一家于香港海关注册的贵金属交易商,核准注册业务包括于 进行发行、赎回及交易黄金支持工具。 海关注册编号A-B-25-03-08913); (ii) 营运托管客户资产的毅盛金融科技(代理人)有限公司(一家获香港信托及公司服务提供商注册办事处发牌的信托及公司服务提供商,获发牌业务包括向客户提供资产托管服务。 发牌编号TC010260); (iii) 研发及营运 espetopia.com 交易平台系统的espetopia Limited; 及关连公司 (iv) 毅盛金融科技(证券)有限公司, 一家获香港证监会准许进行证券代币化业务的公司。

  • Esperanza 攜手天下一幕,拓展香港文化資產新金融

    Esperanza 攜手天下一幕,拓展香港文化資產新金融

    以《大龍鳳》為劇場 IP 案例,連接粉絲參與與娛樂資產代幣化應用,潛在項目儲備規模預計逾港幣20億元

    香港 – Media OutReach Newswire – 2026年5月13日 – 毅盛金融科技(證券)有限公司(「Esperanza」或「公司」)欣然宣布,旗下管理的代幣化基金參與協辦天下一幕有限公司(「天下一幕」)旗下的香港本地劇場 IP 項目《大龍鳳》,雙方已就此簽署合作安排。天下一幕為天下一集團旗下子公司。是次合作標誌著 Esperanza 繼早前娛樂演出代幣化項目後,進一步將其合規金融科技方案延伸至香港劇場、文化 IP 及粉絲參與場景,持續探索文化娛樂資產於新金融模式下的商業價值與應用潛力。

    天下一集團為香港具代表性的綜合影視娛樂企業,業務涵蓋電影、電視、製作、後期製作、藝人管理及相關娛樂產業服務。是次與天下一幕的合作,不僅反映 Esperanza 持續拓展文化娛樂資產代幣化應用場景,亦展示香港本地優質內容及 IP 項目在新金融模式下的更多發展可能。

    作為立足香港、面向亞太的金融科技及真實世界資產代幣化平台,Esperanza 致力於在合規框架下,連接優質資產、合資格投資者、內容持有人、項目營運方及粉絲社群,為文化娛樂項目建立更具透明度、參與度及延展性的金融基礎設施。

    Esperanza 集團行政總裁兼首席法務官梁衞晉表示:

    「《大龍鳳》項目不單是一個劇場合作,更是 Esperanza 在香港文化娛樂資產金融化領域的另一個重要實踐案例。香港一直是亞洲文化、創意及金融交匯的重要城市,我們希望以香港作為起點,將本地優質文化娛樂內容與新型金融科技工具結合,推動內容持有人、項目方、粉絲社群及合資格投資者之間形成更深層次的價值連結。在本項目中,Esperanza 亦將於香港率先推出代幣化體驗應用,讓支持者可透過相關代幣化安排,參與門票兌換、專屬周邊及文化娛樂體驗消費,進一步延伸舞台作品與觀眾之間的互動關係。透過合規代幣化方案,Esperanza 將持續協助更多具文化價值及市場潛力的項目,建立更靈活、更透明及更具參與感的新金融連接模式。」

    天下一集團首席財務官黃詠茵表示:

    「我們很高興能與 Esperanza 團隊展開合作。在現今多元化的娛樂產業生態中,財務架構的創新對於推動創意產業發展至關重要。透過這次合作,我們期待能運用專業的金融科技工具方案,為香港文化娛樂資產開拓更靈活的商業可能。」

    是次合作亦反映 Esperanza 在娛樂及文化資產領域的持續布局。公司正積極發掘更多具備代幣化潛力及商業延展性的項目,涵蓋電影、現場娛樂、劇場 IP、授權業務、AI 沉浸式娛樂、多媒體應用、體驗式場景,以及其他具備真實資產基礎及商業現金流潛力的項目類別。

    Esperanza 預期,隨著亞太區內容產業、粉絲參與模式、人工智能技術及沉浸式娛樂生態快速發展,市場將需要更成熟的合規金融平台,協助優質文化娛樂項目拓展資本連接、社群參與及商業化能力。目前,公司正評估及推進多個相關項目,潛在項目儲備規模預計逾港幣20億元,涵蓋娛樂文化、授權 IP、物業、多媒體、AI 沉浸式娛樂及其他真實世界資產應用方向。

    Esperanza 強調,公司將繼續以合規、透明及可持續發展為核心,推動文化娛樂資產由傳統項目融資及單一消費模式,逐步走向更制度化、數碼化及具參與性的新金融市場模式,為香港及亞太區創意產業創造新的增長空間。

    Hashtag: #Esperanza

    The issuer is solely responsible for the content of this announcement.

    關於毅盛金融科技(證券)有限公司

    毅盛金融科技(證券)有限公司(「Esperanza」或「公司」)證券為一家根據證券及期貨條例(香港法例第571章)獲發牌的公司,獲許可進行第四類(就證券提供意見)及第九類(提供資產管理)業務。Esperanza 於2026年2月13日獲香港證監會確認對Esperanza 就其管理的基金進行代幣化一事並無進一步意見,即正式准許Esperanza 進行證券代幣化業務。

    關於天下一幕有限公司

    天下一幕有限公司(「天下一幕」)為天下一集團旗下公司,參與香港文化娛樂及劇場項目發展。 天下一集團成立於2013年,總部設於香港,是一家致力於電影與娛樂產業發展的綜合企業。本著「創新視野‧敢作敢為」的宗旨,集團建立橫跨整個娛樂產業價值鏈的多元業務版圖,並於亞洲主要市場建立穩定合作及業務布局。欲了解更多資訊,請瀏覽官網

    關於Esperanza金融科技集團

    Esperanza金融科技集團是一家以香港為總部的金融科技公司。集團持牌業務包括 (i) 營運黃金交易及代幣化黃金的毅盛金融科技(商品)有限公司(一家於香港海關註冊的貴金屬交易商,核准註冊業務包括於進行發行、贖回及交易黃金支持工具。海關註冊編號A-B-25-03-08913); (ii) 營運託管客戶資產的毅盛金融科技(代理人)有限公司(一家獲香港信託及公司服務提供者註冊辦事處發牌的信託及公司服務提供者,獲發牌業務包括向客戶提供資產託管服務。發牌編號TC010260);(iii) 研發及營運espetopia.com交易平台系統的Espetopia Limited; 及關連公司 (iv) 毅盛金融科技(證券)有限公司, 一家獲香港證監會准許進行證券代幣化業務的公司。

  • 亞洲國際娛樂展與亞洲綜合度假休閒產業博覽會 2026 今日於澳門隆重開幕: 業界領袖齊聚探索博彩、娛樂及綜合度假村數位創新機遇

    香港 – Media OutReach Newswire – 2026年5月12日 – 亞洲國際娛樂展與亞洲綜合度假休閒產業博覽會今日於澳門威尼斯人隆重開幕,匯聚全球博彩、娛樂及綜合度假村產業領袖,共同探索數位創新如何引領產業邁向下一階段增長與轉型。

    展會將於 2026 年 5 月 12 日至 14 日舉行,預計迎來來自超過 90 個國家及地區的 8000 位業界專業人士。展覽總面積超過 30,000 平方米,集合超過 150 個品牌,全面展示次世代科技、沉浸式體驗方案及數位基礎建設等創新應用。

    根據 Research and Markets 於 2025 年發表的報告,亞洲綜合度假村產業預計將維持約 8% 的年度增長趨勢。在此發展背景下,本次盛會進一步彰顯亞洲作為全球增長核心引擎的重要地位,科技創新與市場需求正以前所未有的速度融合發展。

    勵展博覽集團亞太區商業高級副總裁葉智聰先生表示:「亞洲綜合度假村產業正處於關鍵轉型時期,區內市場持續朝向更豐富的旅遊、娛樂及生活方式體驗發展。透過亞洲國際娛樂展與亞洲綜合度假休閒產業博覽會聯合舉辦,我們希望打造一個連結整個產業價值鏈的重要平台,推動創新協作,並促進產業長遠及可持續增長。」

    於展覽及論壇期間,眾多業界領袖齊聚一堂,積極與同業交流前瞻觀點,並深入探討未來合作機會。

    業界領袖齊聚開幕典禮

    於展覽廳舉行的開幕典禮,為亞洲國際娛樂展與亞洲綜合度假休閒產業博覽會2026 正式揭開序幕,匯聚來自博彩、酒店及娛樂領域的多位重量級產業領袖及高層代表。

    出席嘉賓包括:

    • 澳門特別行政區招商投資促進局主席謝永強先生
    • 澳門特別行政區政府旅遊局代局長程衛東先生
    • 澳門特別行政區政府博彩監察協調局博彩監察廳代廳長鄭艷霞女士
    • 中央人民政府駐澳門特別行政區聯絡辦公室經濟金融部助理趙速先生
    • 美國博彩業協會主席兼行政總裁Mr. Bill Miller
    • 勵展博覽集團亞太區高級副總裁孫周範先生
    • 金沙中國有限公司行政總裁兼執行董事鄭君諾先生
    • 美高梅中國控股有限公司首席執行官及執行董事馮小峰先生
    • 銀河娛樂集團董事程裕昇先生
    • 新濠博亞娛樂董事鍾玉文先生
    • 永利澳門有限公司營運總裁兼執行董事羅偉信先生
    • 澳娛綜合度假股份有限公司首席博彩業務總監李福成先生
    • 澳門娛樂設備廠商會主席陳捷先生

    各界領袖的參與,彰顯產業對推動綜合度假村、博彩及娛樂生態系統創新發展的持續投入與長遠願景。

    由全球產業領袖引領的研討會與峰會議程

    亞洲國際娛樂展與亞洲綜合度假休閒產業博覽會各設三天專屬論壇,由多位資深產業領袖主導,聚焦影響未來產業格局的技術創新、監管發展及市場力量。

    5月12日(星期二),鄭君諾先生,金沙中國有限公司行政總裁兼執行董事將於【亞洲國際娛樂展研討會】及【亞洲綜合度假休閒產業峰會】發表開幕主題演講,從全球產業趨勢切入,為博彩與娛樂產業未來發展奠定策略基調。

    5月14日(星期四),何猷君先生,星競威武集團董事長兼聯席首席執行官及NBA波士頓凱爾特人共同所有人將於亞洲綜合度假休閒產業峰會發表主題演講,深入剖析全球市場轉變及綜合度假村產業的持續演進。

    兩大論壇議程的演講嘉賓包括:

    • Adrian Lee 先生,Google 香港及澳門客戶解決方案銷售主管
    • Al Watson 先生,DataWorks Group 執行長
    • Alan Teo 先生,Hoiana Resort & Golf 首席執行官
    • 程衛東先生,澳門特別行政區政府旅遊局代局長
    • Gregory Hawkins 先生, Bloomberry Resorts Corporation / Solaire Resort 總裁兼首席營運長
    • Joseph Bufalino 先生,Marina Bay Sands 負責任博彩執行總監
    • 馮小峰先生,美高梅中國控股有限公司首席執行官及執行董事
    • Walt Power 先生,The Grand Ho Tram 首席執行官
    • 以及更多

    512日至14日活動亮點

    為期三天的同期盛會,匯聚展覽、教育及產業交流於一體,打造完整且精選的專業生態圈體驗。

    博覽會(512日至14日)
    呈現博彩、娛樂及綜合度假村領域的前沿創新,匯聚超過 150 個品牌,全面展示產業生態系統的最新技術與應用。

    亞洲國際娛樂展研討會(512日至14日)
    提供亞洲市場關鍵洞察、監管趨勢與商業機遇,作為區內博彩與娛樂領域的重要交流平台。

    亞洲綜合度假休閒產業峰會(512日至14日)
    與資深產業領袖共同探索酒店、科技、體育及娛樂領域的策略洞見,推動綜合度假村產業邁向新階段。

    科技論壇(512日)
    由領先專家分享可落地的實務洞察,探討人工智能、機器學習於實際營運的應用,以及數據驅動更智慧且高效的決策方式。

    老虎機行業交流酒會(512日)
    匯聚營運商與供應商進行專屬圓桌交流,共同探索下一代遊戲機台設計,並探討生物識別回饋技術的創新應用。

    G2E Asia 派對(512日)
    於威尼斯主題晚宴中與業界夥伴交流互動,並率先預覽 2027 年備受期待的 VR 賭場套房概念。

    賭桌行業交流酒會(513日)
    促進營運商與供應商之間的深度交流,共同探討博彩演進、創新方向及未來桌面博彩生態系統的發展。

    引領娛樂與綜合度假村的未來發展

    匯聚博彩、娛樂及綜合度假村產業的專業人士——涵蓋營運商、解決方案供應商及酒店業專家——將共同獲取前瞻策略洞見、拓展高端人脈網絡,並深入探索重塑產業未來的創新科技。

    現已開放線上及現場登記。

    如需了解有關亞洲國際娛樂展的更多信息,請訪問www.G2EAsia.com
    如需了解有關亞洲綜合度假休閒產業博覽會的更多信息,請訪問www.AsianIRExpo.com

    Hashtag: #亞洲國際娛樂展 #亞洲綜合度假休閒產業博覽會2026

    The issuer is solely responsible for the content of this announcement.